TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for moderate or severe opioid use disorder at screening and are not seeking opioid use disorder treatment~* Body mass index of \>= 18.0 to \<= 33.0 kg/m\^2~* Females - women of childbearing potential (defined as all women who are not surgically sterile or postmenopausal for at least 1 year prior to informed consent) must have negative pregnancy test prior to enrollment and must agree to use a medically acceptable means of contraception from screening through at least 3 months after the last dose of study drug~* Male subjects with female partners of child-bearing potential must agree to use medically acceptable contraception from screening through at least 3 months after the last dose of study drug~Exclusion Criteria:~* Subjects with any current diagnosis requiring chronic opioid treatment~* Subjects who currently meet the criteria for diagnosis of moderate or severe substance use disorder by DSM-5 criteria for any substances other than opioids, caffeine, or nicotine.~* Subjects who have abused or used buprenorphine within 14 days prior to informed consent.~Other protocol-defined criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- depot buprenorphine (Type: EXPERIMENTAL): Participants were treated with RBP-6000 300-mg in a single subcutaneous injection on Days 1 and 29 following a prior 14 day stabilization period (day -14 to day -1) of buprenorphine and naloxone (SUBOXONE) . Challenges consist of participants receiving on three consecutive days intramuscular (IM) injections of hydromorphone 0 mg (placebo), 6 mg and 18 mg doses during weeks 1-12 in randomized sequential order.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Untreated, stage IIIB with pleural effusion~* Untreated, Stage IV, non-small cell lung cancer~* Recurrent after surgery if no previous radiation therapy or chemotherapy were administered as part of their primary treatment, except for palliative radiotherapy~* 18 years of age or older~* ECOG PS 0, 1 or 2~* At Least one target lesion according to the RECIST Criteria~* Adequate organ and marrow function~Exclusion Criteria:~* Previous cancer history unless they have had curative treatment completed at least 5 years prior to entry.~* No previous radiotherapy, chemotherapy or immunotherapy for NSCLC, except for radiation therapy to the brain to control metastasis, bone to control pain, or lung to relieve bronchial obstruction.~* No radiation therapy for any previous cancer to more than 25% of bone marrow.~* Uncontrolled, intercurrent illness~* Non-study corticosteroids~* Pregnant women~* Peripheral neuropathy greater than grade 1~* Uncontrolled seizures, central nervous system disorders~* Major surgery within 4 weeks of the start of study treatment~* Lack of complete recovery from major surgery.~* Glaucoma~* Lack of physical integrity of upper gastrointestinal tract, inability to swallow tablets~* Severe acquired or hereditary immunodeficiency~* Patients with brain metastases must receive definitive treatment (radiation, surgery or both) and be clinically and radiologically stable for 4 weeks \& off corticosteroids for at least 2 weeks prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 No Dex (Type: OTHER): No Dexamethasone
- 2 Dex (Type: EXPERIMENTAL): Dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Complete treatment in Study CAEB1102-101A without experiencing any clinically significant adverse event or other unmanageable drug toxicity that would preclude continued dosing~2. Confirmation by the Investigator and the Sponsor determine that it is acceptable for the patient to continue dosing with AEB1102~3. If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment~4. If sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration~5. Patient or legal guardian is able and willing to provide written informed consent and where required assent, and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification), prior to any screening procedures~Exclusion Criteria:~1. Clinically significant concurrent disease, serious intercurrent illness, or other extenuating circumstances

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AEB1102 (Type: EXPERIMENTAL): Each patient may receive AEB1102 administered IV for up to approximately 4 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin C Efficacy in Reducing Post Operative Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both gender~* Between 18-75 years old~* ASA class I, II, or III~* Scheduled to undergo laparoscopic cholecystectomy~Exclusion Criteria:~* Intake of anti-inflammatory drug in the past 24 hr~* Allergy to morphine~* History of chemical dependence~* Chronic pain state~* Inability to use PCA pumps~* History of obstructive sleep apnea~* History of severe asthma~* History of COPD~* History of gastroesophageal reflux disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin C (Type: ACTIVE_COMPARATOR): None
- mirinda (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stage III or IV müllerian carcinoma by prelaparoscopic clinical findings including imaging studies (CT, MRI or ultrasonography)~* Cytology of ascites, pleural effusions, or fluids obtained by tumor centesis~* Malignancies of other origins, such as breasts and digestive tract, should be excluded by endoscopy, opaque enema, or ultrasonography when these malignancies are suspected from symptoms, physical examinations or imaging diagnosis.~* CA125\>200U/ml and CEA\<20ng/ml.~* Clinically deemed to be a candidate for debulking surgery without evidence of brain, bone, bone marrow metastases, multiple lung, or multiple liver metastases~* Presence of at least one measurable lesion~* Previously untreated for these malignancies and no history of treatment with chemotherapy or radiotherapy even for other diseases~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3,~* Adequate bone marrow, hepatic, renal, cardiac and respiratory functions, and~* Written informed consent.~Exclusion Criteria:~* Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ~* Pregnant or nursing~* Severe mental disorders~* Systemic and continuous use of steroidal drugs~* Active infections~* Uncontrolled hypertension~* Diabetes mellitus, uncontrolled or controlled with insulin~* History of cardiac failure, unstable angina, myocardial infarction within 6 months prior to the registration~* Liver cirrhosis or bleeding tendency contraindicating debulking surgery~* Intestinal occlusion necessary for surgical treatment~* Hypersensitivity to alcohol

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Yoga and Aerobic Exercise in Psychosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria~* Females aged from 18 to 55.~* Based on the Diagnostic and Statistical Manual (DSM-IV) diagnosed to have schizophrenia, schizoaffective disorder, schizophreniform Psychosis, brief psychotic disorders, psychosis not otherwise specified and delusional disorder. Duration of illness is less than 5 years (including 5 years).~* Cantonese-speaking Chinese.~* Ability to understand the nature of the study and to give an informed consent.~* Fewer than 10 hours of yoga and vigorous aerobic exercise (equivalent to jogging at 10 km/hr) in the previous 3 months.~Exclusion criteria~* Severe physical illness (myocardial infarction, hypertension, fracture, spinal problem), seizure disorders, mental retardation or comorbid substance dependence. Heart rate and blood pressure will be measured at the baseline to exclude the patients with abnormal cardiovascular activities.~* Unstable psychotic symptoms.~* Known pregnancy, or other contraindication to MRI.~* A history of brain trauma or organic brain disease.~* Known history of intellectual disability or special school attendance.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Yoga therapy (Type: EXPERIMENTAL): Hatha yoga including breathing control (10 minutes), body posture(40-45minutes), and relaxation (5 minutes).
- Aerobic exercise (Type: EXPERIMENTAL): Aerobic exercise includes walking on the treadmill for 15-20 minutes and stationary cycling for 25-30 minutes.
- Waitlist group (Type: NO_INTERVENTION): Patients in waiting list will be treated as usual and acted as control group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age or older.~* Patients scheduled to undergo ileostomy reversal.~* Ability to provide informed consent, adhere to study visit schedule, and complete all assessments.~Exclusion Criteria:~* Patients with a history of hypersensitivity or idiosyncratic reactions or intolerance to any local anesthetic, opioid, or propofol.~* Patients who abuse alcohol or other drug substance.~* Patients with severe hepatic impairment.~* Patients currently pregnant or who may become pregnant during the course of the study or who are unwilling to use acceptable means of contraception for at least one month before and one month after dosing.~* Patients with any psychiatric, psychological, or other condition that the Investigator feels may make the patient an inappropriate candidate for this clinical study.~* Patients who have participated in an EXPAREL study within the last 30 days.~* Patients who have received an investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the patient's participation in this study.~In addition, the patient will be ineligible if he/she meets the following criteria during surgery:~* Patients who have any concurrent surgical procedure.~* Patients who receive intraoperative administration of opioids (other than fentanyl or analogs) or any other analgesic, local anesthetics, or anti-inflammatory agents.~* Patients who receive Entereg(R).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 Standard of Care (Type: ACTIVE_COMPARATOR): IV Morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump
- Group 2 EXPAREL (Type: ACTIVE_COMPARATOR): bupivacaine liposome injectable suspension.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject ≥ 9 years of age.~* Diagnosis of primary axillary hyperhidrosis that meets the following criteria: (a) symptoms of hyperhidrosis for at least 6 months' duration, (b) HDSM-Ax of 3 - 4 and (c) a minimum GSP of 50 mg in each axilla with a combined total of at least 150 mg.~* The ability to understand and follow all study-related procedures including study drug administration.~* Sexually active female of childbearing potential (FOCBP)\* must agree to periodic pregnancy testing and use a medically acceptable method of contraception while receiving protocol-assigned product.~Exclusion Criteria:~* In the Investigators opinion, any skin or subcutaneous tissue conditions of the axilla(e).~* Prior use of any prohibited medication(s) or procedure(s) within the specified timeframe for the treatment of axillary hyperhidrosis.~* Anticholinergic agents used to treat conditions such as, but not limited to, hyperhidrosis, asthma, incontinence, gastrointestinal cramps, and muscular spasms by any route of administration.~* Use of any cholinergic drug (e.g. bethanechol) within 28 days.~* Known cause of hyperhidrosis or known history of a condition that may cause hyperhidrosis (i.e., hyperhidrosis secondary to any known cause such hyperthyroidism, diabetes mellitus, medications, etc.).~* Subjects with unstable diabetes mellitus or thyroid disease, history of renal or hepatic impairment, malignancy glaucoma, intestinal obstructive or motility disease, obstructive uropathy, myasthenia gravis, BPH, neurological or psychiatric conditions, Sjögren's or Sicca syndrome, or cardiac abnormalities that may alter or exacerbate sweat production by the use of anticholinergics in the investigator's opinion.~* Subjects with known hypersensitivity to glycopyrrolate, anticholinergics, or any of the components of the topical formulation.~* Subject is pregnant, lactating or is planning to become pregnant during the study.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Sofpironium bromide, 15% gel, once per day
- Vehicle (Type: PLACEBO_COMPARATOR): Vehicle gel, once per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paracetamol Versus Dipyrone After Pediatric Lower Abdominal Surgery in Children With Spinal Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologist (ASA) physical status I and II children undergoing elective lower abdominal surgery~Exclusion Criteria:~* increased intracranial pressure hemorrhagic diathesis infection at the puncture site Those with a known history of allergy to the study drugs

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Paracetamol (Type: ACTIVE_COMPARATOR): 15 mg/kg paracetamol, IV (in the vein)(premixed with 0.9% sodium chloride to a total of 50 ml)single dose
- Dipyrone (Type: ACTIVE_COMPARATOR): 15 mg/kg IV (in the vein)dipyrone received (premixed with 0.9% sodium chloride to a total of 50 ml), single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients (age ≥18 to 60 years), with relapsing-remitting multiple sclerosis (RRMS) defined by the 2010 revised McDonald criteria~* At least 1 documented relapse within the previous year and either ≥1 GdE T1-weighted brain lesions or ≥9 T2-weighted brain lesions at Screening~* Kurtzke Expanded Disability Status Scale (EDSS) score from 0 to 5 (inclusive) at Screening~Exclusion Criteria:~* Manifestation of multiple sclerosis (MS) other than relapsing-remitting multiple sclerosis (RRMS)~* Relapse within the 30 days prior Screening and until administration of the first dose of study drug~* Prior treatment with natalizumab, alemtuzumab, ocrelizumab, daclizumab, rituximab, cladribine, or other B- and T-cell targeting therapies~* Prior total lymphoid irradiation or bone marrow or organ transplantation~* Patients with John Cunningham Virus (JCV) index \>1.5 at Screening~* Past or current Progressive Multi-focal leukoencephalopathy (PML) diagnosis~* Severe renal function impairment as defined by serum creatinine values \>120 micromol per litre

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PB006 (Type: EXPERIMENTAL): Patients with relapsing-remitting multiple sclerosis (RRMS) received intravenous (IV) infusions every 4 weeks of PB006 at a dose of 300 milligram (mg) starting at Visit 1 (Week 0) through Visit 12 (Week 44), for a total of 12 infusions.
- Tysabri (Type: ACTIVE_COMPARATOR): Patients with relapsing-remitting multiple sclerosis (RRMS) received intravenous (IV) infusions every 4 weeks of Tysabri at a dose of 300 milligram (mg) starting at Visit 1 (Week 0) through Visit 12 (Week 44), for a total of 12 infusions. At Week 24, patients in the Tysabri group were re-randomized through a re-randomization step. Patients re-randomized and switched from Tysabri to PB006 at Week 24 still received a total of 12 infusions (6 infusions of Tysabri and 6 infusions of PB006).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age range: 6 to 23 months~* Evidence of AOM~* Recent (within 48 hours) onset of signs and symptoms.~* Middle ear effusion evidenced by the presence of at least 2 of the following: decreased or absent mobility of the tympanic membrane (TM), yellow of white discoloration of the TM, and/or opacification of the TM~* Acute inflammation evidenced by one of the following: 1+ bulging of the TM with either intense erythema or otalgia or 2+ or 3+ bulging of the TM~Exclusion Criteria:~* Toxic appearance (capillary refill \>3 seconds, systolic blood pressure \<60 mm Hg)~* Inpatient hospitalization~* Clinical or anatomical characteristics that might obscure response to treatment (e.g., tympanostomy tubes in place, cleft palate, Down syndrome)~* Sensorineural hearing loss (unilateral or bilateral)~* Allergy to amoxicillin or amoxicillin clavulanate~* Recent treatment of AOM within the last 14 days

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 23 Months
- Healthy Volunteers: f

Study Arms:
- amoxicillin-clavulanate potassium (Type: EXPERIMENTAL): amoxicillin-clavulanate potassium (600 mg/221.5 mg/5 mL; 28:1) administered prior to February 25, 2016 at 90/3.2 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 1) or administered as of February 25, 2016 at 80/2.85 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete